[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549162":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":44,"collaborators":10,"id":46,"slug":10,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients operated for primary and recurrent glioblastoma",null,"Patients operated for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux",[13],"Biological: Relapsed glioblastoma",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","Relapsed glioblastoma","Paired tumor samples diagnosis\u002Frelapse",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Mathieu LARROQUETTE","CONTACT","+33 5 56 79 58 08","mathieu.larroquette@chu-bordeaux.fr",{"name":27,"role":23,"phone":10,"phoneExt":10,"email":28},"Julien ENGELHARDT","julien.engelhardt@chu-bordeaux.fr",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale","RECRUITING","Bordeaux","33000","France",{"type":37,"coordinates":38},"Point",[39,40],-0.58046,44.84124,{"lat":40,"lon":39},[43],{"name":22,"role":23,"phone":10,"phoneExt":10,"email":25},{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100549162",false,"NCT06430424","Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma","Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.","GBrecurr","Inclusion Criteria:\n\n* age \\> 18 years\n* surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux\n\nExclusion Criteria:\n\n* systemic therapy received for non-glioblastoma tumor","ALL","18 Years",{"count":56,"type":57},40,"ESTIMATED","OBSERVATIONAL","Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.",[61,62],"Relapsed Cancer","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",[64,65,66,67,68,69],"Recurrent glioblastoma","Prognostic","Metabolism","Proteomic","Transcriptomic","Microbiota","2025-07-29",{"date":72,"type":73},"2025-07-30","ACTUAL",{"date":75,"type":73},"2024-04-05",{"date":77,"type":57},"2026-04",{"name":5,"class":6},1]